echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first imitation of Haisco's anti-ED drug is approved, and the blockbuster injection will start phase III clinical trials

    The first imitation of Haisco's anti-ED drug is approved, and the blockbuster injection will start phase III clinical trials

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, high scores have been reported frequently by Haisco.


    Drug-related situation

    According to the data, avanafil tablets were originally authorized by Japan's Tanabe Mitsubishi Pharmaceutical Co.


    Source: One-click search on Mi Nei.


    Avanafil tablets are a generic drug product developed by Hisco.


    On the same day, Haisco also issued an announcement stating that the Phase III clinical trial plan of the innovative drug HSK21542 injection of Haisco Pharmaceutical Group Co.


    Basic situation of drugs

    HSK21542 is a new molecular entity compound independently developed by Haisco with completely independent intellectual property rights.


    HSK21542 launched a phase I clinical trial in Australia from October 2019 to October 2020; a phase I clinical trial was launched in China from January 2020 to September 2020; and a phase I clinical trial was launched in China from June 2020 to February 2021 A phase II clinical trial for postoperative analgesia after abdominal laparoscopic surgery.


    Mi Nei Net Bai Yu finishing

    Source: Listed company announcements, Minet database

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.